Printer Friendly

FINLAND RETURNS HALCION TO THE MARKET

 KALAMAZOO, Mich., Jan. 14 /PRNewswire/ -- Following a scientific review, Finnish drug regulators have informed The Upjohn Company (NYSE: UPJ) that it may begin selling Halcion Tablets again immediately. The Finnish Hypnotic Review Committee has been reviewing Halcion data since November 1991.
 "We're pleased with this development," said Theodore Cooper, M.D., Ph.D., Upjohn's Chairman and Chief Executive Officer. "Once again, a measured scientific review has demonstrated to investigators that Halcion is a safe and effective treatment for insomnia when it's used as recommended."
 Jamaica took a similar step in September 1992, returning Halcion to the market after a year's suspension. Jamaica, Finland and Norway suspended Halcion in the wake of the United Kingdom's suspension in October 1991. Upjohn continues to appeal the action in Norway, as well as in the U.K., where, despite a July 1992 recommendation from its scientific advisory committee that 0.125 mg Halcion Tablets should be reinstated, the Licensing Authority is still seeking license revocation.
 In May 1992 in the U.S., the Food and Drug Administration's Psychopharmacologic Drug Products Advisory Committee reviewed Halcion data and concluded that the product is safe and effective when it's used as recommended in the approved labelling.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 1/14/93
 /CONTACT: Kaye Bennett of Upjohn, 616-323-4223/
 (UPJ)


CO: The Upjohn Company ST: Michigan IN: MTC SU:

DH -- DE003 -- 4723 01/14/93 09:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:269
Previous Article:F&M NATIONAL CORPORATION REPORTS INCREASED EARNINGS FOR 1992
Next Article:$14,000,000 TO EDUCATION, RESEARCH, AND CHARITIES DURING 40 YEARS OF GIVING BY THE GERBER COMPANIES FOUNDATION
Topics:


Related Articles
UPJOHN TO DEFEND AND INDEMNIFY PHYSICIANS WHO PRESCRIBE HALCION
UPJOHN ENDORSES EC DECISION ON HALCION
UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
MICHGIAN ATTORNEY JOSEPH MOCH APPOINTED HEAD OF NATIONAL HALCION LITIGATION GROUP
UPJOHN ENDORSES FDA ADVISORY COMMITTEE RECOMMENDATIONS ON HALCION
ADVISORY COMMISSION RECOMMENDS HALCION RETURN TO U.K. MARKET
UPJOHN WINS HALCION CASE
UPJOHN RESPONDS TO WOLFE FDA LETTER
UPJOHN TAKES U.K. GOVERNMENT BODY TO COURT OVER HALCION
UPJOHN WINS MASSACHUSETTS HALCION CASE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters